# Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

> **NCT02013167** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 405 (actual)

## Conditions studied

- Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** Standard of Care Chemotherapy

## Key facts

- **NCT ID:** NCT02013167
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01-03
- **Primary completion:** 2015-12-29
- **Final completion:** 2017-03-14
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013167, "Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02013167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*